Soluble CD52 is an indicator of disease activity in chronic lymphocytic leukemia

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11120%2F17%3A43912971" target="_blank" >RIV/00216208:11120/17:43912971 - isvavai.cz</a>

Alternative codes found

RIV/00064173:_____/17:N0000021

Result on the web

<a href="http://dx.doi.org/10.1080/10428194.2017.1285027" target="_blank" >http://dx.doi.org/10.1080/10428194.2017.1285027</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1080/10428194.2017.1285027" target="_blank" >10.1080/10428194.2017.1285027</a>

Result language

angličtina

Original language name

Soluble CD52 is an indicator of disease activity in chronic lymphocytic leukemia

Original language description

CD52 is a glycoprotein expressed on normal as well as leukemic immune cells and shed as soluble CD52 (sCD52). We studied sCD52 levels in three CLL cohorts: the &apos;early&apos;, the &apos;high-risk&apos;, and the &apos;ibrutinib-treated&apos;. The &apos;high-risk&apos; patients had significantly higher sCD52 levels than the &apos;early&apos; patients. For the &apos;early&apos; patients, high sCD52 levels were associated with a significantly shorter time to first treatment. Regarding prognostic factors, no clear correlations with stage, IGHV, or beta-2-microglobulin were found; in a cox multivariate analysis of the &apos;early&apos; patients, sCD52 and IGHV both had independent prognostic value. Following chemo-immunotherapy, sCD52 decreased in parallel with leukocytes while during ibrutinib treatment and ibrutinib-induced ymphocytosis, sCD52 decreased along with lymph node reductions. In vitro IgM stimulation of CLL cells led to increased sCD52 levels in the medium. Our findings indicate that sCD52 reflects disease activity and potentially treatment efficacy in CLL.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30205 - Hematology

Project

—

Continuities

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Publication year

2017

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Leukemia &amp; Lymphoma

ISSN

1042-8194

e-ISSN

—

Volume of the periodical

58

Issue of the periodical within the volume

10

Country of publishing house

GB - UNITED KINGDOM

Number of pages

7

Pages from-to

2356-2362

UT code for WoS article

000404572000013

EID of the result in the Scopus database

2-s2.0-85011891109